Financial Performance - The company reported a basic earnings per share of CNY 2.44 for 2023, a 134.62% increase compared to CNY 1.04 in 2022[24]. - The diluted earnings per share also stood at CNY 2.44, reflecting the same 134.62% growth year-over-year[24]. - The net profit attributable to shareholders was CNY 416,000,000, which represents 40.09% of the total profit allocated for cash dividends[9]. - The company's operating revenue for 2023 reached approximately ¥2.65 billion, representing a 24.59% increase compared to ¥2.13 billion in 2022[46]. - Net profit attributable to shareholders increased by 130.58% to approximately ¥416.12 million from ¥180.47 million in the previous year[46]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 141.52%, amounting to approximately ¥383.41 million compared to ¥158.75 million in 2022[46]. - The net cash flow from operating activities surged by 174.30% to approximately ¥634.45 million, up from ¥231.30 million in the previous year[46]. - Total assets as of the end of 2023 were approximately ¥7.11 billion, a 3.09% increase from ¥6.89 billion at the end of 2022[46]. - The net assets attributable to shareholders increased by 2.46% to approximately ¥5.65 billion from ¥5.51 billion in 2022[46]. - Total revenue for 2023 reached CNY 2,645,068,738.47, an increase of 25.11% compared to the previous year[79]. - The overall gross profit margin for the main business reached 70.46%, an increase of 1.51 percentage points from the previous year[104]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 10.00 per 10 shares, totaling CNY 166,833,930.00[9]. Research and Development - Research and development expenses accounted for 8.29% of operating revenue, a slight decrease of 0.26 percentage points from 8.55% in 2022[24]. - Research and development expenses amounted to CNY 220,098,318.01, a 20.81% increase from CNY 182,191,781.51 in the previous year, reflecting the company's commitment to innovation[75]. - The company has established an integrated R&D system across China, the US, the UK, France, and Israel, enhancing its technological capabilities and market competitiveness[64]. - The company is focusing on high-end implantable biomaterials, which require complex R&D and have a long development cycle[130]. - The company has several products in various stages of development, including new types of biological gels and cross-linked hyaluronic acid gels[132]. Market Expansion and Product Development - The company is actively expanding its product line in the medical aesthetics sector, including investments in RF and laser medical devices, as well as home-use instruments and botulinum toxin products[66]. - The company is focused on international expansion and has acquired several overseas companies to facilitate the transfer of advanced technologies and products to the domestic market[73]. - The company anticipates continued growth in the medical beauty market, projected to achieve a compound annual growth rate of 15%-20% over the next five years[94]. - The company is leveraging its multi-brand product line and cost advantages to adapt to the new marketing landscape post-volume procurement in the ophthalmology sector[143]. Sales and Revenue Breakdown - Revenue from ophthalmic products was CNY 928,214,432.86, a decrease of 20.57% year-on-year, with a gross margin of 59.11%[79]. - Revenue from medical beauty and wound care products increased by 41.27% to CNY 1,056,860,493.91, with a gross margin of 77.45%[79]. - Revenue from mainland China was CNY 2,191,972,736.84, up 28.20% year-on-year, with a gross margin of 73.65%[79]. - Direct sales accounted for CNY 1,321,405,596.97 in revenue, an increase of 28.49%, with a gross margin of 77.77%[79]. Operational Efficiency - The company has established a procurement center to enhance operational efficiency and reduce costs, focusing on centralized procurement of raw materials and equipment[162]. - The company has entered into significant procurement and sales contracts during the reporting period, enhancing its operational capabilities[82]. Future Outlook - The company’s future outlook includes continued investment in R&D and potential market expansion strategies[24]. - The company is exploring advanced technologies and products in ophthalmology, medical aesthetics, orthopedics, and surgery to ensure sustainable long-term development[147]. Corporate Governance - The company has no non-operating fund occupation by controlling shareholders or related parties[11]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team[8].

Financial Performance - The company recorded a total revenue of RMB 2,634.91 million for the year ended December 31, 2023, representing an increase of RMB 531.47 million or 25.27% compared to the previous year[2]. - Net profit attributable to shareholders was approximately RMB 416.12 million, reflecting a growth of 130.58% compared to the previous year, while the net profit excluding non-recurring items was RMB 383.41 million, up 141.52%[2]. - The gross profit for the year was RMB 1,853.51 million, compared to RMB 1,446.92 million in 2022, indicating a significant increase in profitability[3]. - The company reported a total comprehensive income of RMB 404.44 million for the year, significantly higher than RMB 100.70 million in 2022[4]. - The basic and diluted earnings per share for the year were RMB 2.44, compared to RMB 1.04 in the previous year, showcasing strong earnings growth[4]. - The total tax expense for the year 2023 amounted to RMB 95,991,000, an increase of 111.1% compared to RMB 45,395,000 in 2022[30]. Research and Development - Research and development expenses amounted to approximately RMB 220.10 million, an increase of RMB 37.91 million or 20.81% year-over-year, accounting for 8.35% of total revenue[2]. - The company is focusing on expanding its ophthalmic and aesthetic innovation product lines, with several key R&D projects progressing smoothly[48]. - The hydrophobic injection aspheric intraocular lens product has been approved for registration and market launch in June 2023, while other products are in various stages of clinical trials and registration[48]. - The company has initiated clinical trials for the innovative hydrophobic molded aspheric trifocal artificial lens in July 2023[56]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 1.00 per share for the year ended December 31, 2023, compared to RMB 0.40 per share in 2022, and recommended a bonus issue of 4 new shares for every 10 existing shares[2]. - The total number of H-shares repurchased in 2023 was 3,872,400, with a total expenditure of HKD 166,589,234.00[89]. - The total number of A-shares repurchased in 2023 was 1,089,486, with a total expenditure of RMB 117,145,262.95[90]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 6,389.55 million, slightly up from RMB 6,381.12 million in the previous year[5]. - Current assets increased to RMB 3,750.14 million from RMB 3,532.12 million, indicating improved liquidity[5]. - The company’s total liabilities amounted to RMB 407.95 million as of December 31, 2023, compared to RMB 118.26 million in 2022[40]. - The current portion of total liabilities was RMB 216.63 million, while the non-current portion was RMB 191.32 million[40]. Revenue Breakdown - Revenue from mainland China was RMB 2,181,814 thousand, up 28.5% from RMB 1,699,078 thousand in 2022[22]. - The ophthalmology product line generated RMB 924.65 million in revenue, accounting for 35.10% of total revenue, with a year-on-year growth of 20.72%[47]. - The medical beauty and wound care product line reported revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a significant year-on-year growth of 41.44%[47]. - The orthopedic product line's revenue reached RMB 474.26 million, making up 18.00% of total revenue, with a year-on-year increase of 22.71%[47]. Market Position and Strategy - The company has been recognized as a high-tech enterprise, allowing a preferential tax rate of 15% for certain subsidiaries in 2023[6]. - The company aims to accelerate the localization of the ophthalmic industry in China and become a globally recognized comprehensive ophthalmic product manufacturer[50]. - The company has established exclusive distribution rights for high-end corneal reshaping lenses in mainland China, enhancing its market share and influence[56]. - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, while enhancing research and development capabilities[69]. Compliance and Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[93]. - The audit committee reviewed the audited consolidated financial statements and annual results for the year ending December 31, 2023[94]. - The annual report containing all data required by the Hong Kong Listing Rules will be sent to shareholders and published on the relevant websites in due course[95].

Investment Rating - The report assigns a "Buy" rating for both A-shares and H-shares of the company, with a target price of 119.5 CNY for A-shares and 54.1 HKD for H-shares [2][11]. Core Views - The company has reported a strong growth in annual performance for 2023, with revenue expected to be in the range of 3.83 to 3.83 billion CNY, representing a year-on-year increase of 4-4.3 billion CNY [2][4]. - The net profit attributable to the parent company is projected to be 4.16 billion CNY, showing a year-on-year growth of 130.58% [2][4]. - The company has maintained stable operations, particularly in the aesthetic medicine segment, with significant sales performance in hyaluronic acid products [2][4]. - The company has developed a comprehensive product matrix covering four major business areas, including hyaluronic acid fillers and laser equipment, with ongoing research and development efforts [2][4]. Financial Summary - Revenue for 2023 is expected to reach 2,654 million CNY, with a growth rate of 24.6% compared to the previous year [2][7]. - The net profit for 2023 is projected at 416 million CNY, reflecting a growth rate of 130.3% [2][7]. - Earnings per share (EPS) for 2023 is estimated to be 2.42 CNY, with a corresponding price-to-earnings (P/E) ratio of 43.23 [2][7]. - The company’s EBITDA is expected to be 594 million CNY for 2023, indicating a significant increase from previous years [2][7].

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海昊海生物科技股份有限公司 2021 年 A 股限制性股票激励计划预留授予部分第一个归属 期归属条件成就及作废部分已授予但尚未归属的限制性股 票相关事项之 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海昊海生物科技股份有限公司 2021 年 A 股限制性股票激励计划预留授予部分第一个归属期归 属条件成就及作废部分已授予但尚未归属的限制性股票相关事 项之法律意见书 致：上海昊海生物科技股份有限公司 第一部分 引言 上海市锦天城律师事务所（以下简称"本所"）接受上海昊海生物科技股份 有限公司（以下简称"昊海生科"或"公司"）的委托，指派周健律师和尹英爱 律师作为公司特聘专项法律顾问，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司股权激励管理办法》《上海证券交易所科创板股票上市 规则》《科创板上市公司自律监管指南第 4 号——股权激励信息披露》及其 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2023年11月6日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 | H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月3日 | | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 20,700 ...

Financial Performance - Basic earnings per share for the third quarter were CNY 0.71, a 36.54% increase compared to the same period last year[5] - The company's net profit attributable to shareholders for the year-to-date period increased significantly, leading to a basic earnings per share of CNY 1.91, up from CNY 0.93 in the previous year[17] - The total comprehensive income for the period was CNY 323,974,453.15, compared to CNY 113,155,858.77 in the same period last year[17] - The net profit attributable to shareholders for Q3 2023 was ¥121,568,232.09, reflecting a growth of 34.00% year-over-year[21] - The net profit attributable to shareholders for the year-to-date period was ¥326,802,993.69, which is a significant increase of 102.04% year-over-year[21] - The company reported a net profit of CNY 326,967,441.02 for the first three quarters of 2023, compared to CNY 166,259,426.07 in the same period of 2022, reflecting an increase of about 96.66%[41] Revenue and Sales Growth - The company's operating revenue for Q3 2023 was ¥668,887,006.49, representing an increase of 8.80% compared to the same period last year[21] - For the year-to-date period, the operating revenue reached ¥1,981,789,458.11, marking a 25.23% increase compared to the same period last year[21] - The company experienced a significant increase in sales of its medical beauty hyaluronic acid products, with revenue growth exceeding 50% compared to the previous year[25] - The company’s sales revenue for the first three quarters of 2023 was CNY 2,153,855,868.18, compared to CNY 1,688,544,097.45 in the same period of 2022, reflecting an increase of approximately 27.5%[42] Research and Development - The total R&D investment amounted to CNY 52,763,351.61, representing 7.89% of operating revenue, an increase of 0.65 percentage points year-on-year[5] - The proportion of R&D investment to operating revenue has shown a consistent upward trend, indicating a strong commitment to innovation[5] - Research and development expenses for the first three quarters of 2023 were CNY 154,154,668.27, compared to CNY 121,221,455.33 in the same period of 2022, marking an increase of about 27.2%[41] Cash Flow and Assets - The net cash flow from operating activities increased by 116.37% year-to-date, primarily due to significant growth in operating revenue[9] - The net cash flow from operating activities for the year-to-date period was ¥391,564,343.48, showing a growth of 116.37% compared to the previous year[21] - Cash and cash equivalents at the end of the reporting period were CNY 406,363,089.01, down from CNY 682,889,664.04 at the end of 2022, a decrease of approximately 40.43%[39] - The cash inflow from investment activities totaled CNY 1,089,423,627.13 for the current period, compared to CNY 990,170,755.22 in the previous period, indicating an increase of about 10.03%[37] Equity and Liabilities - Total assets at the end of the reporting period were CNY 7,089,426,530.74, reflecting a 2.86% increase from the end of the previous year[5] - The company reported a total equity attributable to shareholders of CNY 5,704,966,947.12, a 3.45% increase from the previous year[5] - The total liabilities as of September 30, 2023, were ¥1,011,068,562.86, compared to ¥990,013,737.98 at the end of the previous period[33] - The company’s total liabilities increased to CNY 3,715,795,672.92 as of September 30, 2023, from CNY 3,532,115,166.92 at the end of 2022, representing a growth of approximately 5.18%[39]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2023年第三季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。本公告亦同時在上海證券交易所網站發佈。 茲載列本集團截至2023年9月30日止三個月及九個月未經審計業績（「第三季度報 告」）。第三季度報告所載財務數據乃根據中國企業會計準則編製，且未經審計。 提請本公司潛在投資者及股東注意潛在投資風險。 第三季度報告以中英文版本編製。有任何歧義，概以第三季度報告中文版本為準。 承董事會命 上海 ...

Financial Performance - The company recorded a revenue of approximately RMB 1,305.71 million for the six months ended June 30, 2023, representing an increase of approximately RMB 349.44 million or 36.54% compared to the same period in 2022[9]. - The net profit attributable to equity holders of the company was approximately RMB 205.24 million, a significant increase of approximately RMB 134.21 million or 188.94% compared to the same period in 2022[9][14]. - The company’s basic earnings per share for the reporting period were RMB 1.20, compared to RMB 0.41 in the same period last year[9]. - The gross profit for the same period is RMB 926.42 million, up from RMB 666.78 million, reflecting a gross margin improvement[77]. - The company reported a net profit of RMB 205,235,000 for the six months ended June 30, 2023, compared to RMB 114,764,000 for the same period in 2022, representing an increase of approximately 78.8%[86]. - The company achieved a profit attributable to ordinary equity holders of approximately RMB 205.24 million, a significant increase of about RMB 134.21 million or 188.94% compared to RMB 71.03 million in the same period last year[57]. Revenue Breakdown - The revenue breakdown by product line for the first half of 2023 showed significant growth in all categories, with ophthalmology products contributing RMB 479.15 million (36.70% of total revenue) and medical aesthetics products contributing RMB 483.50 million (37.03%)[10]. - Revenue from ophthalmic products was RMB 479,149 thousand, up 35.4% from RMB 354,161 thousand year-on-year[104]. - Revenue from medical beauty and wound care products increased to RMB 483,499 thousand, representing a 47.8% growth compared to RMB 327,057 thousand in the previous year[104]. - The artificial lens segment reported revenue of approximately RMB 202.92 million, an increase of RMB 74.91 million, or 58.51%, driven by a rapid recovery in cataract surgeries nationwide[17]. - The company’s hyaluronic acid products achieved revenue of approximately RMB 255.24 million, an increase of RMB 136.44 million compared to the same period last year, representing a growth rate of 114.85%[35]. Research and Development - Research and development expenses amounted to approximately RMB 101.39 million, an increase of approximately RMB 24.68 million or 32.17% year-on-year, accounting for 7.77% of total revenue[9][11]. - Clinical trials for multiple key R&D projects, including various types of intraocular lenses, are progressing smoothly, with one product already approved for registration in June 2023[11]. - The company is focusing on expanding its ophthalmology and medical aesthetics product lines, with several key research and development projects progressing smoothly[11]. - The company plans to focus on the development of new products in the ophthalmology sector, including various types of intraocular lenses and myopia control products, in the second half of 2023[46]. Market Position and Strategy - The company is actively developing high-end artificial lens products, including astigmatism correction and multifocal lenses, supported by national research and development plans[21]. - The company has established a complete industrial chain layout for artificial lenses, integrating upstream raw material production and downstream sales channels[21]. - The market share of the company's ophthalmic viscoelastic products decreased from 50.83% in 2021 to 44.52% in 2022, but it remains the largest in China for 16 consecutive years[15]. - The company has exclusive distribution rights for high-end orthokeratology lenses in mainland China, enhancing its market share and influence in this segment[25]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately RMB 7,254.17 million, with net assets attributable to equity holders amounting to RMB 5,709.62 million, reflecting increases of approximately RMB 361.77 million and RMB 195.01 million, respectively, compared to the end of 2022[14]. - The total current assets as of June 30, 2023, were approximately RMB 3,878.57 million, an increase of about RMB 346.45 million or 9.81% from the end of 2022[59]. - The total liabilities of the group as of June 30, 2023, are approximately RMB 1,163.60 million, with a debt-to-asset ratio of 16.04%, an increase of 1.68 percentage points from 14.36% as of December 31, 2022[67]. - The company’s total liabilities to total assets ratio increased, indicating a higher leverage position compared to the previous year[83]. Employee and Compensation - As of June 30, 2023, the total number of employees in the group is 2,123, with 810 in production, 341 in R&D, 646 in sales and marketing, 88 in finance, and 238 in administration[62]. - The total employee compensation for the reporting period is approximately RMB 315.53 million[62]. Corporate Governance - The company has complied with all applicable code provisions of the Corporate Governance Code during the reporting period[182]. - The company continues to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[182]. - The interim financial statements were approved by the board on August 17, 2023, and published on the Hong Kong Stock Exchange website[157]. Dividend Policy - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023[9]. - The proposed final dividend for the year ended December 31, 2022, is RMB 0.40 per share, while no interim dividend is recommended for the six months ended June 30, 2023[116].

FF304 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | | 06826 | H 股 說明 | | | | | | 發行股份 | (註6及7) | | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | | 2023年8月25日 | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 116,000 | 0.0677 % | | | % | | 於2023年8月28日已回購但尚未註銷的股份 | | | | | | | | | 變動日期 | 2023年8月28日 | | | | | | | | 於下列日期結束時的 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-039 上海昊海生物科技股份有限公司 股东减持股份期限届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 1 6,151,186 股，占公司目前总股本 171,287,974 股的 3.5911%。本次减持计划实施 完毕，现将具体情况公告如下。 注：持股比例系占本次减持计划披露时公司总股本 171,271,000 股的比例。 上述减持主体无一致行动人。 2 重要内容提示： 股东持股的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）股东楼国梁先生于本 次减持计划实施前持有公司无限售条件流通股股份为 7,125,075 股，占减持计划 披露时公司总股本 171,271,000 股的 4.1601%。 上述股份来源于公司首次公开发行前，已于 2020 年 10 月 30 日解除限售并 上市流通。 减持计划的实施结果情况 公司于 2023 年 2 月 18 日披露了《上海昊海生物科技股份有限公司股东减持 股份计划公告》（公告编号： ...